Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cervical cancer screening.

Dorothy J Wiley1, Bradley J Monk, Emmanuel Masongsong

  • 1Division of Primary Care, School of Nursing, University of California at Los Angeles, Los Angeles, CA 90095-6919, USA. dwiley@ucla.edu

Current Oncology Reports
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same author

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Gynecologic oncology·2026
Same author

Endometriosis and ovarian cancer risk.

Gynecologic oncology·2026
Same author

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Gynecologic oncology·2026
Same author

Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.

Gynecologic oncology·2026
Same author

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Lancet (London, England)·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Cervical cancer screening using cytology remains essential. Adding human papillomavirus (HPV) DNA testing for women over 30 may extend screening intervals to three years, improving early detection and management.

Area of Science:

  • Oncology
  • Gynecology
  • Infectious Diseases

Background:

  • Cervical cancer is primarily caused by persistent human papillomavirus (HPV) infections.
  • Current screening relies on cytology, but primary prevention through HPV vaccination is still developing.
  • Cervical cancer screening strategies require ongoing evaluation for efficacy and cost-effectiveness.

Purpose of the Study:

  • To evaluate the role of molecular HPV DNA testing in conjunction with existing cervical cancer screening protocols.
  • To determine optimal screening intervals and identify high-risk populations requiring closer monitoring.
  • To assess the cost-effectiveness of integrating HPV DNA testing into routine cervical cancer screening.

Main Methods:

  • Review of current cervical cancer screening guidelines and technologies.

Related Experiment Videos

  • Analysis of cost-effectiveness data for HPV DNA testing in women over 30.
  • Identification of patient groups with increased risk for HPV infection and cervical atypia.

    • Main Results:

    • Periodic cytology screening is recommended for young-adult women.
    • Molecular HPV DNA testing for women over 30 may permit extending the screening interval to 3 years.
    • High-risk populations, including organ transplant recipients, DES-exposed women, and HIV-infected women, need closer surveillance.

    Conclusions:

    • Cervical cancer screening strategies will likely continue to involve cytology for the foreseeable future.
    • Integrating HPV DNA testing offers potential for optimized screening intervals and resource allocation.
    • Tailored monitoring for high-risk individuals is crucial for effective cervical cancer prevention and management.